<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35455363</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2076-393X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Vaccines</Title>
          <ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">614</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10040614</ELocationID>
        <Abstract>
          <AbstractText>A significant part of the world population has been affected by the devastating SARS-CoV-2 infection. It has deleterious effects on mental and physical health and global economic conditions. Evidence suggests that the pathogenesis of SARS-CoV-2 infection may result in immunopathology such as neutrophilia, lymphopenia, decreased response of type I interferon, monocyte, and macrophage dysregulation. Even though most individuals infected with the SARS-CoV-2 virus suffer mild symptoms similar to flu, severe illness develops in some cases, including dysfunction of multiple organs. Excessive production of different inflammatory cytokines leads to a cytokine storm in COVID-19 infection. The large quantities of inflammatory cytokines trigger several inflammation pathways through tissue cell and immune cell receptors. Such mechanisms eventually lead to complications such as acute respiratory distress syndrome, intravascular coagulation, capillary leak syndrome, failure of multiple organs, and, in severe cases, death. Thus, to devise an effective management plan for SARS-CoV-2 infection, it is necessary to comprehend the start and pathways of signaling for the SARS-CoV-2 infection-induced cytokine storm. This article discusses the current findings of SARS-CoV-2 related to immunopathology, the different paths of signaling and other cytokines that result in a cytokine storm, and biomarkers that can act as early signs of warning for severe illness. A detailed understanding of the cytokine storm may aid in the development of effective means for controlling the disease's immunopathology. In addition, noting the biomarkers and pathophysiology of severe SARS-CoV-2 infection as early warning signs can help prevent severe complications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ahmad</LastName>
            <ForeName>Rahnuma</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-7379-0822</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Medical College for Women and Hospital, Plot No 4 Road 8/9, Sector-1, Dhaka 1230, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haque</LastName>
            <ForeName>Mainul</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-6124-7993</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Vaccines (Basel)</MedlineTA>
        <NlmUniqueID>101629355</NlmUniqueID>
        <ISSNLinking>2076-393X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ARDS</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2 virus</Keyword>
        <Keyword MajorTopicYN="N">biomarkers</Keyword>
        <Keyword MajorTopicYN="N">cytokine storm</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">multiorgan failure</Keyword>
        <Keyword MajorTopicYN="N">pathogenesis</Keyword>
        <Keyword MajorTopicYN="N">severe illness</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The author declares that they do not have any financial involvement or affiliations with any organization, association, or entity directly or indirectly involved with the subject matter or materials presented in this article. This includes honoraria, expert testimony, employment, ownership of stocks or options, patents or grants received or pending, or royalties.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35455363</ArticleId>
        <ArticleId IdType="pmc">PMC9026643</ArticleId>
        <ArticleId IdType="doi">10.3390/vaccines10040614</ArticleId>
        <ArticleId IdType="pii">vaccines10040614</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>World Health Organization  . Coronavirus Disease (COVID-2019) Situation Reports. WHO Press, World Health Organization; Geneva, Switzerland: 2021.  [(accessed on 25 November 2021)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdool Karim S.S., de Oliveira T. New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications. N. Engl. J. Med. 2021;384:1866–1868. doi: 10.1056/NEJMc2100362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2100362</ArticleId>
            <ArticleId IdType="pmc">PMC8008749</ArticleId>
            <ArticleId IdType="pubmed">33761203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization  . Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. WHO Press, World Health Organization; Geneva, Switzerland: 2021.  [(accessed on 28 November 2021)].  Available online:  https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention  . SARS-CoV-2 Variant Classifications and Definitions. Centers for Disease Control and Prevention; Atlanta, GA, USA: 2021.  [(accessed on 9 March 2022)].  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Fan E., Beitler J.R., Brochard L., Calfee C.S., Ferguson N.D., Slutsky A.S. COVID-19-associated acute respiratory distress syndrome: Is a different approach to management warranted? Lancet Respir. Med. 2020;8:816–821. doi: 10.1016/S2213-2600(20)30304-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30304-0</ArticleId>
            <ArticleId IdType="pmc">PMC7338016</ArticleId>
            <ArticleId IdType="pubmed">32645311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradley B.T., Maioli H., Johnston R., Chaudhry I., Fink S.L., Xu H. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: A case series. Lancet. 2020;396:320–332. doi: 10.1016/S0140-6736(20)31305-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31305-2</ArticleId>
            <ArticleId IdType="pmc">PMC7365650</ArticleId>
            <ArticleId IdType="pubmed">32682491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Struyf T., Deeks J.J., Dinnes J., Takwoingi Y., Davenport C., Leeflang M.M. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst. Rev. 2020;7:13665.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId>
            <ArticleId IdType="pmc">PMC7135076</ArticleId>
            <ArticleId IdType="pubmed">32007143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salamanna F., Maglio M., Landini M.P., Fini M. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front. Med. 2020;7:594495. doi: 10.3389/fmed.2020.594495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2020.594495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ. Res. 2020;126:1456–1474. doi: 10.1161/CIRCRESAHA.120.317015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317015</ArticleId>
            <ArticleId IdType="pmc">PMC7188049</ArticleId>
            <ArticleId IdType="pubmed">32264791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Li H.B., Lyu J.R., Lei X.M., Li W., Wu G. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 2020;96:19–24. doi: 10.1016/j.ijid.2020.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2020.04.027</ArticleId>
            <ArticleId IdType="pmc">PMC7165079</ArticleId>
            <ArticleId IdType="pubmed">32311451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId>
            <ArticleId IdType="pmc">PMC7095418</ArticleId>
            <ArticleId IdType="pubmed">32015507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId>
            <ArticleId IdType="pmc">PMC7102627</ArticleId>
            <ArticleId IdType="pubmed">32142651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA. 2020;117:7001–7003. doi: 10.1073/pnas.2002589117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId>
            <ArticleId IdType="pmc">PMC7132130</ArticleId>
            <ArticleId IdType="pubmed">32165541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010;11:373–384. doi: 10.1038/ni.1863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1863</ArticleId>
            <ArticleId IdType="pubmed">20404851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373–381. doi: 10.1016/j.immuni.2006.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2006.08.007</ArticleId>
            <ArticleId IdType="pubmed">16979569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020;80:607–613. doi: 10.1016/j.jinf.2020.03.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId>
            <ArticleId IdType="pmc">PMC7194613</ArticleId>
            <ArticleId IdType="pubmed">32283152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson L.A., Canna S.W., Schulert G.S., Volpi S., Lee P.Y., Kernan K.F. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–1063. doi: 10.1002/art.41285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41285</ArticleId>
            <ArticleId IdType="pmc">PMC7262347</ArticleId>
            <ArticleId IdType="pubmed">32293098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId>
            <ArticleId IdType="pmc">PMC7270045</ArticleId>
            <ArticleId IdType="pubmed">32192578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tufan A., Avanoğlu Güler A., Matucci-Cerinic M. COVID-19, immune system response, hyper inflammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 2020;50:620–632. doi: 10.3906/sag-2004-168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3906/sag-2004-168</ArticleId>
            <ArticleId IdType="pmc">PMC7195984</ArticleId>
            <ArticleId IdType="pubmed">32299202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangalmurti N., Hunter C.A. Cytokine Storms: Understanding COVID-19. Immunity. 2020;53:19–25. doi: 10.1016/j.immuni.2020.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC7321048</ArticleId>
            <ArticleId IdType="pubmed">32610079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Xie X., Tu Z., Fu J., Xu D., Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 2021;6:255. doi: 10.1038/s41392-021-00679-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId>
            <ArticleId IdType="pmc">PMC8261820</ArticleId>
            <ArticleId IdType="pubmed">34234112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davila M.L., Riviere I., Wang X., Bartido S., Park J., Curran K. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014;6:224ra25. doi: 10.1126/scitranslmed.3008226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509–1518. doi: 10.1056/NEJMoa1215134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215134</ArticleId>
            <ArticleId IdType="pmc">PMC4058440</ArticleId>
            <ArticleId IdType="pubmed">23527958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>London N.R., Zhu W., Bozza F.A., Smith M.C., Greif D.M., Sorensen L.K. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci. Transl. Med. 2010;2:23ra19. doi: 10.1126/scitranslmed.3000678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3000678</ArticleId>
            <ArticleId IdType="pmc">PMC2875996</ArticleId>
            <ArticleId IdType="pubmed">20375003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imus P.H., Blackford A.L., Bettinotti M., Luznik L., Fuchs E.J., Huff C.A. Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2019;25:2431–2437. doi: 10.1016/j.bbmt.2019.07.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2019.07.027</ArticleId>
            <ArticleId IdType="pmc">PMC7402409</ArticleId>
            <ArticleId IdType="pubmed">31394272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wadia P.P., Tambur A.R. Yin and yang of cytokine regulation in solid organ graft rejection and tolerance. Clin. Lab. Med. 2008;28:469–479. doi: 10.1016/j.cll.2008.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cll.2008.08.001</ArticleId>
            <ArticleId IdType="pubmed">19028264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int. Immunopharmacol. 2020;89:107087. doi: 10.1016/j.intimp.2020.107087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2020.107087</ArticleId>
            <ArticleId IdType="pmc">PMC7550173</ArticleId>
            <ArticleId IdType="pubmed">33075714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017;39:517–528. doi: 10.1007/s00281-017-0639-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-017-0639-8</ArticleId>
            <ArticleId IdType="pubmed">28555385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IQWiG  . The Innate and Adaptive Immune Systems. Institute for Quality and Efficiency in Health Care (IQWiG); Cologne, Germany: 2006.  [(accessed on 9 March 2022)].  InformedHealth.org [Internet] Available online:  https://www.ncbi.nlm.nih.gov/books/NBK279396/</Citation>
        </Reference>
        <Reference>
          <Citation>Marshall J.S., Warrington R., Watson W., Kim H.L. An introduction to immunology and immunopathology. Allergy Asthma Clin. Immunol. 2018;14((Suppl. S2)):49. doi: 10.1186/s13223-018-0278-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13223-018-0278-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156898</ArticleId>
            <ArticleId IdType="pubmed">30263032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alberts B., Johnson A., Lewis J.  Molecular Biology of the Cell. 4th ed. Garland Science; New York, NY, USA: 2002.  [(accessed on 9 March 2022)].  The Adaptive Immune System. Chapter 24. Available online:  https://www.ncbi.nlm.nih.gov/books/NBK21070.</Citation>
        </Reference>
        <Reference>
          <Citation>Diamond M.S., Kanneganti T.D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 2022;23:165–176. doi: 10.1038/s41590-021-01091-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId>
            <ArticleId IdType="pmc">PMC8935980</ArticleId>
            <ArticleId IdType="pubmed">35105981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasuga Y., Zhu B., Jang K.J., Yoo J.S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 2021;53:723–736. doi: 10.1038/s12276-021-00602-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-021-00602-1</ArticleId>
            <ArticleId IdType="pmc">PMC8099713</ArticleId>
            <ArticleId IdType="pubmed">33953325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanneganti T.D. Intracellular innate immune receptors: Life inside the cell. Immunol. Rev. 2020;297:5–12. doi: 10.1111/imr.12912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12912</ArticleId>
            <ArticleId IdType="pmc">PMC7592123</ArticleId>
            <ArticleId IdType="pubmed">32856334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwasaki A. A virological view of innate immune recognition. Annu. Rev. Microbiol. 2012;66:177–196. doi: 10.1146/annurev-micro-092611-150203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-micro-092611-150203</ArticleId>
            <ArticleId IdType="pmc">PMC3549330</ArticleId>
            <ArticleId IdType="pubmed">22994491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. J. Innate Immun. 2020;12:4–20. doi: 10.1159/000503030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503030</ArticleId>
            <ArticleId IdType="pmc">PMC6959104</ArticleId>
            <ArticleId IdType="pubmed">31610541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connell P., Aldhamen Y.A. Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. Hum. Vaccin. Immunother. 2020;16:2980–2991. doi: 10.1080/21645515.2020.1802974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2020.1802974</ArticleId>
            <ArticleId IdType="pmc">PMC8641610</ArticleId>
            <ArticleId IdType="pubmed">32878546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boechat J.L., Chora I., Morais A., Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology—Current perspectives. Pulmonology. 2021;27:423–437. doi: 10.1016/j.pulmoe.2021.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pulmoe.2021.03.008</ArticleId>
            <ArticleId IdType="pmc">PMC8040543</ArticleId>
            <ArticleId IdType="pubmed">33867315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amarante-Mendes G.P., Adjemian S., Branco L.M., Zanetti L.C., Weinlich R., Bortoluci K.R. Pattern Recognition Receptors and the Host Cell Death Molecular Machinery. Front. Immunol. 2018;9:2379. doi: 10.3389/fimmu.2018.02379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02379</ArticleId>
            <ArticleId IdType="pmc">PMC6232773</ArticleId>
            <ArticleId IdType="pubmed">30459758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009;22:240–273. doi: 10.1128/CMR.00046-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CMR.00046-08</ArticleId>
            <ArticleId IdType="pmc">PMC2668232</ArticleId>
            <ArticleId IdType="pubmed">19366914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combadière B. Immunité adaptative contre le virus SARS-CoV-2 (Adaptive immunity against SARS-CoV-2) Med. Sci. 2020;36:908–913. doi: 10.1051/medsci/2020168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1051/medsci/2020168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonilla F.A., Oettgen H.C. Adaptive immunity. J. Allergy Clin. Immunol. 2010;125((Suppl. S2)):S33–S40. doi: 10.1016/j.jaci.2009.09.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.09.017</ArticleId>
            <ArticleId IdType="pubmed">20061006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paust S., Senman B., von Andrian U.H. Adaptive immune responses mediated by natural killer cells. Immunol. Rev. 2010;235:286–296. doi: 10.1111/j.0105-2896.2010.00906.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0105-2896.2010.00906.x</ArticleId>
            <ArticleId IdType="pmc">PMC2911633</ArticleId>
            <ArticleId IdType="pubmed">20536570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC7803150</ArticleId>
            <ArticleId IdType="pubmed">33497610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel M., Shahjin F., Cohen J.D., Hasan M., Machhi J., Chugh H. The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiol. Rev. 2021;45:fuab035. doi: 10.1093/femsre/fuab035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/femsre/fuab035</ArticleId>
            <ArticleId IdType="pmc">PMC8632753</ArticleId>
            <ArticleId IdType="pubmed">34160586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah V.K., Firmal P., Alam A., Ganguly D., Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons from the Past. Front. Immunol. 2020;11:1949. doi: 10.3389/fimmu.2020.01949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01949</ArticleId>
            <ArticleId IdType="pmc">PMC7426442</ArticleId>
            <ArticleId IdType="pubmed">32849654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Trincado J.L., Gomez-Perosanz M., Reche P.A. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J. Immunol. Res. 2017;2017:2680160. doi: 10.1155/2017/2680160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/2680160</ArticleId>
            <ArticleId IdType="pmc">PMC5763123</ArticleId>
            <ArticleId IdType="pubmed">29445754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7265853</ArticleId>
            <ArticleId IdType="pubmed">32513566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García L.F. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front. Immunol. 2020;11:1441. doi: 10.3389/fimmu.2020.01441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01441</ArticleId>
            <ArticleId IdType="pmc">PMC7308593</ArticleId>
            <ArticleId IdType="pubmed">32612615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou T.G., Adler F.R., Cahill B.C., Cox D.R., Cox J.E., Grant G.J. SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection. Physiol. Rep. 2021;9:e14761. doi: 10.14814/phy2.14761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14814/phy2.14761</ArticleId>
            <ArticleId IdType="pmc">PMC7903990</ArticleId>
            <ArticleId IdType="pubmed">33625796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min Y.Q., Huang M., Sun X., Deng F., Wang H., Ning Y.J. Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput. Struct. Biotechnol. J. 2021;19:4217–4225. doi: 10.1016/j.csbj.2021.07.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.csbj.2021.07.023</ArticleId>
            <ArticleId IdType="pmc">PMC8310780</ArticleId>
            <ArticleId IdType="pubmed">34336145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouayad A. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV. Rev. Med. Virol. 2020;30:1–9. doi: 10.1002/rmv.2135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rmv.2135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 2020;20:355–362. doi: 10.1038/s41577-020-0331-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId>
            <ArticleId IdType="pmc">PMC7201395</ArticleId>
            <ArticleId IdType="pubmed">32376901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amor S., Fernández Blanco L., Baker D. Innate immunity during SARS-CoV-2: Evasion strategies and activation trigger hypoxia and vascular damage. Clin. Exp. Immunol. 2020;202:193–209. doi: 10.1111/cei.13523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13523</ArticleId>
            <ArticleId IdType="pmc">PMC7537271</ArticleId>
            <ArticleId IdType="pubmed">32978971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou R., To K.K., Wong Y.C., Liu L., Zhou B., Li X. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864–877.e5. doi: 10.1016/j.immuni.2020.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.07.026</ArticleId>
            <ArticleId IdType="pmc">PMC7402670</ArticleId>
            <ArticleId IdType="pubmed">32791036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Gayo E., Yu X.G. Role of Dendritic Cells in Natural Immune Control of HIV-1 Infection. Front. Immunol. 2019;10:1306. doi: 10.3389/fimmu.2019.01306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01306</ArticleId>
            <ArticleId IdType="pmc">PMC6563724</ArticleId>
            <ArticleId IdType="pubmed">31244850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai G., Du M., Bossé Y., Albrecht H., Qin F., Luo X. Xiao, F. SARS-CoV-2 Impairs Dendritic Cells and Regulates DC-SIGN Gene Expression in Tissues. Int. J. Mol. Sci. 2021;22:9228.  doi: 10.3390/ijms22179228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22179228</ArticleId>
            <ArticleId IdType="pmc">PMC8431536</ArticleId>
            <ArticleId IdType="pubmed">34502134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122–1127. doi: 10.1126/science.abm8108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abm8108</ArticleId>
            <ArticleId IdType="pubmed">35271343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alipoor S.D., Mortaz E., Jamaati H., Tabarsi P., Bayram H., Varahram M. COVID-19: Molecular and Cellular Response. Front. Cell. Infect. Microbiol. 2021;11:563085. doi: 10.3389/fcimb.2021.563085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2021.563085</ArticleId>
            <ArticleId IdType="pmc">PMC7904902</ArticleId>
            <ArticleId IdType="pubmed">33643932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen W., Su W., Tang H., Le W., Zhang X., Zheng Y. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6:31. doi: 10.1038/s41421-020-0168-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41421-020-0168-9</ArticleId>
            <ArticleId IdType="pmc">PMC7197635</ArticleId>
            <ArticleId IdType="pubmed">32377375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front. Physiol. 2018;9:113. doi: 10.3389/fphys.2018.00113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2018.00113</ArticleId>
            <ArticleId IdType="pmc">PMC5826082</ArticleId>
            <ArticleId IdType="pubmed">29515456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–1535. doi: 10.1126/science.1092385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1092385</ArticleId>
            <ArticleId IdType="pubmed">15001782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y.M., Zheng Y., Yu Y., Wang Y., Huang Q., Qian F. Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. EMBO J. 2020;39:e105896. doi: 10.15252/embj.2020105896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.2020105896</ArticleId>
            <ArticleId IdType="pmc">PMC7737620</ArticleId>
            <ArticleId IdType="pubmed">33140861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId>
            <ArticleId IdType="pmc">PMC7042881</ArticleId>
            <ArticleId IdType="pubmed">32031570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Martínez-Colón G.J., McKechnie J.L. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020;26:1070–1076. doi: 10.1038/s41591-020-0944-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId>
            <ArticleId IdType="pmc">PMC7382903</ArticleId>
            <ArticleId IdType="pubmed">32514174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronit A., Berg R.M.G., Bay J.T., Haugaard A.K., Ahlström M.G., Burgdorf K.S. Compartmental immunophenotyping in COVID-19 ARDS: A case series. J. Allergy Clin. Immunol. 2021;147:81–91. doi: 10.1016/j.jaci.2020.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2020.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC7581505</ArticleId>
            <ArticleId IdType="pubmed">32979342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulte-Schrepping J., Reusch N., Paclik D., Baßler K., Schlickeiser S., Zhang B. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell. 2020;182:1419–1440.e23. doi: 10.1016/j.cell.2020.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.001</ArticleId>
            <ArticleId IdType="pmc">PMC7405822</ArticleId>
            <ArticleId IdType="pubmed">32810438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palsson-McDermott E.M., Curtis A.M., Goel G., Lauterbach M.A.R., Sheedy F.J., Gleeson L.E. Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction. It Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. Cell Metab. 2015;21:347. doi: 10.1016/j.cmet.2015.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2015.01.017</ArticleId>
            <ArticleId IdType="pubmed">29510100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McElvaney O.J., McEvoy N.L., McElvaney O.F., Carroll T.P., Murphy M.P., Dunlea D.M., Ní Choileáin O. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am. J. Respir. Crit. Care Med. 2020;202:812–821. doi: 10.1164/rccm.202005-1583OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.202005-1583OC</ArticleId>
            <ArticleId IdType="pmc">PMC7491404</ArticleId>
            <ArticleId IdType="pubmed">32584597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenne C.N., Wong C.H., Zemp F.J., McDonald B., Rahman M.M., Forsyth P.A. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe. 2013;13:169–180. doi: 10.1016/j.chom.2013.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2013.01.005</ArticleId>
            <ArticleId IdType="pubmed">23414757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabcanovic-Musija F., Obermayer A., Stoiber W., Krautgartner W.D., Steinbacher P., Winterberg N. Neutrophil extracellular trap (NET) formation characterizes stable and exacerbated COPD and correlates with airflow limitation. Respir. Res. 2015;16:59. doi: 10.1186/s12931-015-0221-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12931-015-0221-7</ArticleId>
            <ArticleId IdType="pmc">PMC4455316</ArticleId>
            <ArticleId IdType="pubmed">25994149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikacenic C., Moore R., Dmyterko V., West T.E., Altemeier W.A., Liles W.C. Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia. Crit. Care. 2018;22:358. doi: 10.1186/s13054-018-2290-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13054-018-2290-8</ArticleId>
            <ArticleId IdType="pmc">PMC6307268</ArticleId>
            <ArticleId IdType="pubmed">30587204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bendib I., de Chaisemartin L., Granger V., Schlemmer F., Maitre B., Hüe S. Neutrophil Extracellular Traps Are Elevated in Patients with Pneumonia-related Acute Respiratory Distress Syndrome. Anesthesiology. 2019;130:581–591. doi: 10.1097/ALN.0000000000002619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ALN.0000000000002619</ArticleId>
            <ArticleId IdType="pubmed">30676417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId>
            <ArticleId IdType="pmc">PMC7092819</ArticleId>
            <ArticleId IdType="pubmed">32109013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veras F.P., Pontelli M.C., Silva C.M., Toller-Kawahisa J.E., de Lima M., Nascimento D.C. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 2020;217:e20201129. doi: 10.1084/jem.20201129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20201129</ArticleId>
            <ArticleId IdType="pmc">PMC7488868</ArticleId>
            <ArticleId IdType="pubmed">32926098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuo Y., Yalavarthi S., Shi H., Gockman K., Zuo M., Madison J.A. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:e138999. doi: 10.1172/jci.insight.138999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId>
            <ArticleId IdType="pmc">PMC7308057</ArticleId>
            <ArticleId IdType="pubmed">32329756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraro S.P., De Souza G.F., Gallo S.W., Da Silva B.K., De Oliveira S.D., Vinolo M.A.R. Respiratory Syncytial Virus induces the classical ROS-dependent NETosis through PAD-4 and necroptosis pathways activation. Sci. Rep. 2018;8:14166. doi: 10.1038/s41598-018-32576-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-32576-y</ArticleId>
            <ArticleId IdType="pmc">PMC6154957</ArticleId>
            <ArticleId IdType="pubmed">30242250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng O.Z., Palaniyar N. NET balancing: A problem in inflammatory lung diseases. Front. Immunol. 2013;4:1. doi: 10.3389/fimmu.2013.00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2013.00001</ArticleId>
            <ArticleId IdType="pmc">PMC3553399</ArticleId>
            <ArticleId IdType="pubmed">23355837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borges L., Pithon-Curi T.C., Curi R., Hatanaka E. COVID-19, and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps. Mediat. Inflamm. 2020;2020:8829674. doi: 10.1155/2020/8829674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/8829674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762–768. doi: 10.1093/cid/ciaa248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId>
            <ArticleId IdType="pmc">PMC7108125</ArticleId>
            <ArticleId IdType="pubmed">32161940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F., Nie J., Wang H., Zhao Q., Xiong Y., Deng L. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J. Infect. Dis. 2020;221:1762–1769. doi: 10.1093/infdis/jiaa150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiaa150</ArticleId>
            <ArticleId IdType="pmc">PMC7184346</ArticleId>
            <ArticleId IdType="pubmed">32227123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K., Chen W., Zhang Z., Deng Y., Lian J.Q., Du P. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020;5:283. doi: 10.1038/s41392-020-00426-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00426-x</ArticleId>
            <ArticleId IdType="pmc">PMC7714896</ArticleId>
            <ArticleId IdType="pubmed">33277466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. doi: 10.1126/science.abc6027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abc6027</ArticleId>
            <ArticleId IdType="pmc">PMC7402632</ArticleId>
            <ArticleId IdType="pubmed">32661059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30116-8</ArticleId>
            <ArticleId IdType="pmc">PMC7118626</ArticleId>
            <ArticleId IdType="pubmed">32171062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19) Front. Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId>
            <ArticleId IdType="pmc">PMC7205903</ArticleId>
            <ArticleId IdType="pubmed">32425950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–1741. doi: 10.1111/all.14238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.14238</ArticleId>
            <ArticleId IdType="pubmed">32077115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Liu S., Liu J., Zhang Z., Wan X., Huang B. COVID-19: Immunopathogenesis and Immunotherapeutics. Signal Transduct. Target. Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00243-2</ArticleId>
            <ArticleId IdType="pmc">PMC7381863</ArticleId>
            <ArticleId IdType="pubmed">32712629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H., Li H., Guo L., Liang Y., Li J., Wang X. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. PLoS Pathog. 2020;16:e1008949.  doi: 10.1371/journal.ppat.1008949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1008949</ArticleId>
            <ArticleId IdType="pmc">PMC7660522</ArticleId>
            <ArticleId IdType="pubmed">33180882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Xu W., Hu G., Xia S., Sun Z., Liu Z. Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell. Mol. Immunol. 2020;17:894. doi: 10.1038/s41423-020-0498-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-020-0498-4</ArticleId>
            <ArticleId IdType="pmc">PMC7348563</ArticleId>
            <ArticleId IdType="pubmed">32651469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue Y., Nabar N.R., Shi C.S., Kamenyeva O., Xiao X., Hwang I.Y. SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9:904. doi: 10.1038/s41419-018-0917-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0917-y</ArticleId>
            <ArticleId IdType="pmc">PMC6125346</ArticleId>
            <ArticleId IdType="pubmed">30185776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan Y.X., Tan T.H., Lee M.J., Tham P.Y., Gunalan V., Druce J. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. J. Virol. 2007;81:6346–6355. doi: 10.1128/JVI.00090-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.00090-07</ArticleId>
            <ArticleId IdType="pmc">PMC1900074</ArticleId>
            <ArticleId IdType="pubmed">17428862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan L., Wang Q., Zhang D., Ding J., Huang Q., Tang Y.Q. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct. Target. Ther. 2020;5:33. doi: 10.1038/s41392-020-0148-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0148-4</ArticleId>
            <ArticleId IdType="pmc">PMC7100419</ArticleId>
            <ArticleId IdType="pubmed">32296069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao X. COVID-19: Immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–270. doi: 10.1038/s41577-020-0308-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId>
            <ArticleId IdType="pmc">PMC7143200</ArticleId>
            <ArticleId IdType="pubmed">32273594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D., Chen Y., Liu H., Jia Y., Li F., Wang W. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: Insights from ERS-COVID-19 study. Signal Transduct. Target. Ther. 2020;5:62. doi: 10.1038/s41392-020-0163-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0163-5</ArticleId>
            <ArticleId IdType="pmc">PMC7198844</ArticleId>
            <ArticleId IdType="pubmed">32371949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadarangani M., Marchant A., Kollmann T.R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 2021;21:475–484. doi: 10.1038/s41577-021-00578-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00578-z</ArticleId>
            <ArticleId IdType="pmc">PMC8246128</ArticleId>
            <ArticleId IdType="pubmed">34211186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quast I., Tarlinton D. B cell memory: Understanding COVID-19. Immunity. 2021;54:205–210. doi: 10.1016/j.immuni.2021.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2021.01.014</ArticleId>
            <ArticleId IdType="pmc">PMC7826135</ArticleId>
            <ArticleId IdType="pubmed">33513337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson L.B. The immune system. Essays Biochem. 2016;60:275–301. doi: 10.1042/EBC20160017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/EBC20160017</ArticleId>
            <ArticleId IdType="pmc">PMC5091071</ArticleId>
            <ArticleId IdType="pubmed">27784777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palm A.E., Henry C. Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination. Front. Immunol. 2019;10:1787. doi: 10.3389/fimmu.2019.01787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01787</ArticleId>
            <ArticleId IdType="pmc">PMC6685390</ArticleId>
            <ArticleId IdType="pubmed">31417562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiakolas A.R., Kramer K.J., Johnson N.V., Wall S.C., Suryadevara N., Wrapp D. Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nat. Biotechnol. :2022. doi: 10.1038/s41587-022-01232-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41587-022-01232-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–644. doi: 10.1038/s41586-021-03207-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId>
            <ArticleId IdType="pmc">PMC8221082</ArticleId>
            <ArticleId IdType="pubmed">33461210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner J.S., Kim W., Kalaidina E., Goss C.W., Rauseo A.M., Schmitz A.J. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595:421–425. doi: 10.1038/s41586-021-03647-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId>
            <ArticleId IdType="pubmed">34030176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima N., Klausner J.D. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect. Dis. 2022;22:12–14. doi: 10.1016/S1473-3099(21)00676-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(21)00676-9</ArticleId>
            <ArticleId IdType="pmc">PMC8575467</ArticleId>
            <ArticleId IdType="pubmed">34762853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Çölkesen F., Kepenek Kurt E., Vatansev H., Korkmaz C., Çölkesen F., Yücel F. Memory B cells and serum immunoglobulins are associated with disease severity and mortality in patients with COVID-19. Postgrad. Med. J. 2022 doi: 10.1136/postgradmedj-2021-140540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/postgradmedj-2021-140540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vo H.T.M., Maestri A., Auerswald H., Sorn S., Lay S., Seng H. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort. Front. Immunol. 2022;13:817905. doi: 10.3389/fimmu.2022.817905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2022.817905</ArticleId>
            <ArticleId IdType="pmc">PMC8853741</ArticleId>
            <ArticleId IdType="pubmed">35185909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y. Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. Clin. Infect. Dis. 2020;71:2027–2034. doi: 10.1093/cid/ciaa344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId>
            <ArticleId IdType="pmc">PMC7184337</ArticleId>
            <ArticleId IdType="pubmed">32221519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Zhou X., Zhu C., Song Y., Feng F., Qiu Y. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients with COVID-19. Front. Mol. Biosci. 2020;7:157. doi: 10.3389/fmolb.2020.00157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmolb.2020.00157</ArticleId>
            <ArticleId IdType="pmc">PMC7350507</ArticleId>
            <ArticleId IdType="pubmed">32719810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blundell P.A., Le N.P.L., Allen J., Watanabe Y., Pleass R.J. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors. J. Biol. Chem. 2017;292:12994–13007. doi: 10.1074/jbc.M117.795047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.795047</ArticleId>
            <ArticleId IdType="pmc">PMC5546038</ArticleId>
            <ArticleId IdType="pubmed">28620050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keeler S.P., Fox J.M. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Viruses. 2021;13:1037.  doi: 10.3390/v13061037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v13061037</ArticleId>
            <ArticleId IdType="pmc">PMC8226613</ArticleId>
            <ArticleId IdType="pubmed">34072720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben Mkaddem S., Benhamou M., Monteiro R.C. Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools. Front. Immunol. 2019;10:811. doi: 10.3389/fimmu.2019.00811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00811</ArticleId>
            <ArticleId IdType="pmc">PMC6481281</ArticleId>
            <ArticleId IdType="pubmed">31057544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koenderman L. Inside-Out Control of Fc-Receptors. Front. Immunol. 2019;10:544. doi: 10.3389/fimmu.2019.00544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00544</ArticleId>
            <ArticleId IdType="pmc">PMC6437074</ArticleId>
            <ArticleId IdType="pubmed">30949181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E., Yagita H. Activation of NK cell cytotoxicity. Mol. Immunol. 2005;42:501–510. doi: 10.1016/j.molimm.2004.07.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2004.07.034</ArticleId>
            <ArticleId IdType="pubmed">15607806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Erp E.A., Luytjes W., Ferwerda G., van Kasteren P.B. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. Front. Immunol. 2019;10:548. doi: 10.3389/fimmu.2019.00548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00548</ArticleId>
            <ArticleId IdType="pmc">PMC6438959</ArticleId>
            <ArticleId IdType="pubmed">30967872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay M.Z., Wiehe K., Pollara J. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. Front. Immunol. 2019;10:332. doi: 10.3389/fimmu.2019.00332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00332</ArticleId>
            <ArticleId IdType="pmc">PMC6404786</ArticleId>
            <ArticleId IdType="pubmed">30873178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adeniji O.S., Giron L.B., Purwar M., Zilberstein N.F., Kulkarni A.J., Shaikh M.W. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. MBio. 2021;12:e00281-21. doi: 10.1128/mBio.00281-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.00281-21</ArticleId>
            <ArticleId IdType="pmc">PMC8092230</ArticleId>
            <ArticleId IdType="pubmed">33879594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan C.E.Z., Seah S.G.K., Chye H., Massey S., Torres M., Lim A.P.C. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE. 2021;16:e0253487.  doi: 10.1371/journal.pone.0253487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0253487</ArticleId>
            <ArticleId IdType="pmc">PMC8221499</ArticleId>
            <ArticleId IdType="pubmed">34161386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bournazos S., Gupta A., Ravetch J.V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 2020;20:633–643. doi: 10.1038/s41577-020-00410-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-00410-0</ArticleId>
            <ArticleId IdType="pmc">PMC7418887</ArticleId>
            <ArticleId IdType="pubmed">32782358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan Y., Shang J., Sun S., Tai W., Chen J., Geng Q. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 2020;94:e02015-19. doi: 10.1128/JVI.02015-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.02015-19</ArticleId>
            <ArticleId IdType="pmc">PMC7022351</ArticleId>
            <ArticleId IdType="pubmed">31826992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nimmerjahn F., Ravetch J.V. Fc-receptors as regulators of immunity. Adv. Immunol. 2007;96:179–204. doi: 10.1016/S0065-2776(07)96005-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-2776(07)96005-8</ArticleId>
            <ArticleId IdType="pubmed">17981207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Zuno G.A., Matuz-Flores M.G., González-Estevez G., Nicoletti F., Turrubiates-Hernández F.J., Mangano K. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. Int. J. Immunopathol. Pharmacol. 2021;35:20587384211050199. doi: 10.1177/20587384211050199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/20587384211050199</ArticleId>
            <ArticleId IdType="pmc">PMC8512237</ArticleId>
            <ArticleId IdType="pubmed">34632844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narasimhan P.B., Marcovecchio P., Hamers A.A.J., Hedrick C.C. Nonclassical Monocytes in Health and Disease. Annu. Rev. Immunol. 2019;37:439–456. doi: 10.1146/annurev-immunol-042617-053119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-042617-053119</ArticleId>
            <ArticleId IdType="pubmed">31026415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G., Qi F., Li H., Yang Q., Wang H., Wang X. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov. 2020;6:73. doi: 10.1038/s41421-020-00225-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41421-020-00225-2</ArticleId>
            <ArticleId IdType="pmc">PMC7574992</ArticleId>
            <ArticleId IdType="pubmed">33101705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honda K., Takaoka A., Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349–360. doi: 10.1016/j.immuni.2006.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2006.08.009</ArticleId>
            <ArticleId IdType="pubmed">16979567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen S., Thomsen A.R. Sensing of RNA viruses: A review of innate immune receptors involved in recognizing RNA virus invasion. J. Virol. 2012;86:2900–2910. doi: 10.1128/JVI.05738-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.05738-11</ArticleId>
            <ArticleId IdType="pmc">PMC3302314</ArticleId>
            <ArticleId IdType="pubmed">22258243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park A., Iwasaki A. Type I and Type III Interferons—Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27:870–878. doi: 10.1016/j.chom.2020.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC7255347</ArticleId>
            <ArticleId IdType="pubmed">32464097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Møller R. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036–1045.e9. doi: 10.1016/j.cell.2020.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId>
            <ArticleId IdType="pmc">PMC7227586</ArticleId>
            <ArticleId IdType="pubmed">32416070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galani I.E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021;22:32–40. doi: 10.1038/s41590-020-00840-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-00840-x</ArticleId>
            <ArticleId IdType="pubmed">33277638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopecky-Bromberg S.A., Martínez-Sobrido L., Frieman M., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 2007;81:548–557. doi: 10.1128/JVI.01782-06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01782-06</ArticleId>
            <ArticleId IdType="pmc">PMC1797484</ArticleId>
            <ArticleId IdType="pubmed">17108024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siu K.L., Kok K.H., Ng M.J., Poon V.K.M., Yuen K.Y., Zheng B.J. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK. TBK1/IKKepsilon complex. J. Biol. Chem. 2009;284:16202–16209. doi: 10.1074/jbc.M109.008227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.008227</ArticleId>
            <ArticleId IdType="pmc">PMC2713514</ArticleId>
            <ArticleId IdType="pubmed">19380580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minakshi R., Padhan K., Rani M., Khan N., Ahmad F., Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS ONE. 2009;4:e8342.  doi: 10.1371/journal.pone.0008342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0008342</ArticleId>
            <ArticleId IdType="pmc">PMC2791231</ArticleId>
            <ArticleId IdType="pubmed">20020050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y., Li W., Gao T., Cui Y., Jin Y., Li P. The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination. J. Virol. 2017;91:e02143-16. doi: 10.1128/JVI.02143-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.02143-16</ArticleId>
            <ArticleId IdType="pmc">PMC5375661</ArticleId>
            <ArticleId IdType="pubmed">28148787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster B., Assil S., Dreux M. Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells. J. Virol. 2016;90:10050–10053. doi: 10.1128/JVI.01692-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01692-16</ArticleId>
            <ArticleId IdType="pmc">PMC5105643</ArticleId>
            <ArticleId IdType="pubmed">27605675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cervantes-Barragan L., Lewis K.L., Firner S., Thiel V., Hugues S., Reith W. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc. Natl. Acad. Sci. USA. 2012;109:3012–3017. doi: 10.1073/pnas.1117359109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1117359109</ArticleId>
            <ArticleId IdType="pmc">PMC3286988</ArticleId>
            <ArticleId IdType="pubmed">22315415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z., Ren L., Zhang L., Zhong J., Xiao Y., Jia Z. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe. 2020;27:883–890.e2. doi: 10.1016/j.chom.2020.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC7196896</ArticleId>
            <ArticleId IdType="pubmed">32407669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193. doi: 10.1016/j.chom.2016.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2016.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC4752723</ArticleId>
            <ArticleId IdType="pubmed">26867177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Channappanavar R., Fehr A.R., Zheng J., Wohlford-Lenane C., Abrahante J.E., Mack M. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Investig. 2019;129:3625–3639. doi: 10.1172/JCI126363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI126363</ArticleId>
            <ArticleId IdType="pmc">PMC6715373</ArticleId>
            <ArticleId IdType="pubmed">31355779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId>
            <ArticleId IdType="pmc">PMC7080116</ArticleId>
            <ArticleId IdType="pubmed">32125452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146:128–136.e4. doi: 10.1016/j.jaci.2020.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC7233239</ArticleId>
            <ArticleId IdType="pubmed">32425269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laing A.G., Lorenc A., Del Molino Del Barrio I., Das A., Fish M., Monin L. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 2020;26:1623–1635. doi: 10.1038/s41591-020-1038-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-1038-6</ArticleId>
            <ArticleId IdType="pubmed">32807934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price C.C., Altice F.L., Shyr Y., Koff A., Pischel L., Goshua G. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients with Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest. 2020;158:1397–1408. doi: 10.1016/j.chest.2020.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2020.06.006</ArticleId>
            <ArticleId IdType="pmc">PMC7831876</ArticleId>
            <ArticleId IdType="pubmed">32553536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992–1000.e3. doi: 10.1016/j.chom.2020.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC7172841</ArticleId>
            <ArticleId IdType="pubmed">32320677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano T., Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 2020;52:731–733. doi: 10.1016/j.immuni.2020.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC7175868</ArticleId>
            <ArticleId IdType="pubmed">32325025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId>
            <ArticleId IdType="pmc">PMC4176007</ArticleId>
            <ArticleId IdType="pubmed">25190079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8:959–970. doi: 10.2217/imt-2016-0020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2016-0020</ArticleId>
            <ArticleId IdType="pubmed">27381687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulhar R., Ashraf M.A., Jialal I.  StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2021. Physiology, Acute Phase Reactants.</Citation>
        </Reference>
        <Reference>
          <Citation>Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 2001;21:1621–1632. doi: 10.1128/MCB.21.5.1621-1632.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.21.5.1621-1632.2001</ArticleId>
            <ArticleId IdType="pmc">PMC86708</ArticleId>
            <ArticleId IdType="pubmed">11238899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLoughlin R.M., Hurst S.M., Nowell M.A., Harris D.A., Horiuchi S., Morgan L.W., Wilkinson T.S., Yamamoto N., Topley N., Jones S.A. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol. 2004;172:5676–5683. doi: 10.4049/jimmunol.172.9.5676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.172.9.5676</ArticleId>
            <ArticleId IdType="pubmed">15100312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Meer I.M., de Maat M.P., Bots M.L., Breteler M.M., Meijer J., Kiliaan A.J., Hofman A., Witteman J.C. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: The Rotterdam Study. Arterioscler. Thromb. Vasc. Biol. 2002;22:838–842. doi: 10.1161/01.ATV.0000016249.96529.B8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.ATV.0000016249.96529.B8</ArticleId>
            <ArticleId IdType="pubmed">12006399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang S., Dong N.G., Liu J.P., Wang Y., Shi J.W., Wei Z.J. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013;33:615–622. doi: 10.1007/s11596-013-1168-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11596-013-1168-x</ArticleId>
            <ArticleId IdType="pubmed">24142708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon Cytokine Res. 2009;29:313–326. doi: 10.1089/jir.2008.0027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jir.2008.0027</ArticleId>
            <ArticleId IdType="pmc">PMC2755091</ArticleId>
            <ArticleId IdType="pubmed">19441883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474. doi: 10.1126/science.abb8925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb8925</ArticleId>
            <ArticleId IdType="pubmed">32303591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875–879. doi: 10.1038/nm1267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1267</ArticleId>
            <ArticleId IdType="pmc">PMC7095783</ArticleId>
            <ArticleId IdType="pubmed">16007097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glowacka I., Bertram S., Herzog P., Pfefferle S., Steffen I., Muench M.O. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 2010;84:1198–1205. doi: 10.1128/JVI.01248-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01248-09</ArticleId>
            <ArticleId IdType="pmc">PMC2798380</ArticleId>
            <ArticleId IdType="pubmed">19864379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schieffer B., Luchtefeld M., Braun S., Hilfiker A., Hilfiker-Kleiner D., Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ. Res. 2000;87:1195–1201. doi: 10.1161/01.RES.87.12.1195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.87.12.1195</ArticleId>
            <ArticleId IdType="pubmed">11110778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recinos A 3rd LeJeune W.S., Sun H., Lee C.Y., Tieu B.C. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194:125–133. doi: 10.1016/j.atherosclerosis.2006.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.atherosclerosis.2006.10.013</ArticleId>
            <ArticleId IdType="pmc">PMC2196437</ArticleId>
            <ArticleId IdType="pubmed">17109863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catanzaro M., Fagiani F., Racchi M., Corsini E., Govoni S., Lanni C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 2020;5:84. doi: 10.1038/s41392-020-0191-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0191-1</ArticleId>
            <ArticleId IdType="pmc">PMC7255975</ArticleId>
            <ArticleId IdType="pubmed">32467561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schluns K.S., Kieper W.C., Jameson S.C., Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat. Immunol. 2000;1:426–432. doi: 10.1038/80868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/80868</ArticleId>
            <ArticleId IdType="pubmed">11062503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seddon B., Tomlinson P., Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 2003;4:680–686. doi: 10.1038/ni946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni946</ArticleId>
            <ArticleId IdType="pubmed">12808452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fry T.J., Mackall C.L. The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance. J. Immunol. 2005;174:6571–6576. doi: 10.4049/jimmunol.174.11.6571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.11.6571</ArticleId>
            <ArticleId IdType="pubmed">15905493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA. 2001;98:8732–8737. doi: 10.1073/pnas.161126098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.161126098</ArticleId>
            <ArticleId IdType="pmc">PMC37504</ArticleId>
            <ArticleId IdType="pubmed">11447288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saraiva M., O’Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010;10:170–181. doi: 10.1038/nri2711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2711</ArticleId>
            <ArticleId IdType="pubmed">20154735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L., Zhang H., Dauphars D.J., He Y.W. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol. 2021;42:3–5. doi: 10.1016/j.it.2020.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2020.10.012</ArticleId>
            <ArticleId IdType="pmc">PMC7605819</ArticleId>
            <ArticleId IdType="pubmed">33214057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect. 2020;9:1123–1130. doi: 10.1080/22221751.2020.1770129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId>
            <ArticleId IdType="pmc">PMC7473317</ArticleId>
            <ArticleId IdType="pubmed">32475230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Qin L., Zhang P., Li K., Liang L., Sun J. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020;5:e139834. doi: 10.1172/jci.insight.139834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vignali D.A., Kuchroo V.K. IL-12 family cytokines: Immunological playmakers. Nat. Immunol. 2012;13:722–728. doi: 10.1038/ni.2366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2366</ArticleId>
            <ArticleId IdType="pmc">PMC4158817</ArticleId>
            <ArticleId IdType="pubmed">22814351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Shea J.J., Paul W.E. Regulation of T(H)1 differentiation--controlling the controllers. Nat. Immunol. 2002;3:506–508. doi: 10.1038/ni0602-506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni0602-506</ArticleId>
            <ArticleId IdType="pubmed">12032561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg S.A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 2014;192:5451–5458. doi: 10.4049/jimmunol.1490019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1490019</ArticleId>
            <ArticleId IdType="pmc">PMC6293462</ArticleId>
            <ArticleId IdType="pubmed">24907378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu X., Xu M., Song Y., Li Y., Zhang H., Zhang J. Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II-independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways. J. Biol. Chem. 2018;293:19771–19784. doi: 10.1074/jbc.RA118.003668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.003668</ArticleId>
            <ArticleId IdType="pmc">PMC6314126</ArticleId>
            <ArticleId IdType="pubmed">30352872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X., Cheng G., Malek T.R. The importance of regulatory T-cell heterogeneity in maintaining self-tolerance. Immunol. Rev. 2014;259:103–114. doi: 10.1111/imr.12163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12163</ArticleId>
            <ArticleId IdType="pmc">PMC3983566</ArticleId>
            <ArticleId IdType="pubmed">24712462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Wang W., Yin J., Ouyang Y., Pang L., Feng Y. The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia. Cell Death Dis. 2020;11:429. doi: 10.1038/s41419-020-2636-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2636-4</ArticleId>
            <ArticleId IdType="pmc">PMC7276960</ArticleId>
            <ArticleId IdType="pubmed">32513989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cua D.J., Tato C.M. Innate IL-17-producing cells: The sentinels of the immune system. Nat. Rev. Immunol. 2010;10:479–489. doi: 10.1038/nri2800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2800</ArticleId>
            <ArticleId IdType="pubmed">20559326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes I.B., Mease P.J., Ritchlin C.T., Rahman P., Gottlieb A.B., Kirkham B. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2-year results from the phase 3 FUTURE 2 study. Rheumatology. 2017;56:1993–2003. doi: 10.1093/rheumatology/kex301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kex301</ArticleId>
            <ArticleId IdType="pmc">PMC5850284</ArticleId>
            <ArticleId IdType="pubmed">28968735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacha O., Sallman M.A., Evans S.E. COVID-19: A case for inhibiting IL-17? Nat. Rev. Immunol. 2020;20:345–346. doi: 10.1038/s41577-020-0328-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0328-z</ArticleId>
            <ArticleId IdType="pmc">PMC7194244</ArticleId>
            <ArticleId IdType="pubmed">32358580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asrani P., Hassan M.I. SARS-CoV-2 mediated lung inflammatory responses in host: Targeting the cytokine storm for therapeutic interventions. Mol. Cell. Biochem. 2021;476:675–687. doi: 10.1007/s11010-020-03935-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-020-03935-z</ArticleId>
            <ArticleId IdType="pmc">PMC7563911</ArticleId>
            <ArticleId IdType="pubmed">33064288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquereau S., Kumar A., Herbein G. Targeting TNF, and TNF Receptor Pathway in HIV-1 Infection: From Immune Activation to Viral Reservoirs. Viruses. 2017;9:64.  doi: 10.3390/v9040064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v9040064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filik H., Avan A.A. Electrochemical immunosensors for the detection of cytokine tumor necrosis factor-alpha: A review. Talanta. 2020;211:120758. doi: 10.1016/j.talanta.2020.120758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.talanta.2020.120758</ArticleId>
            <ArticleId IdType="pubmed">32070602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aggarwal B.B. Signaling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 2003;3:745–756. doi: 10.1038/nri1184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1184</ArticleId>
            <ArticleId IdType="pubmed">12949498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014;15:135–147. doi: 10.1038/nrm3737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3737</ArticleId>
            <ArticleId IdType="pubmed">24452471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutta J., Fan Y., Gupta N., Fan G., Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25:6800–6816. doi: 10.1038/sj.onc.1209938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209938</ArticleId>
            <ArticleId IdType="pubmed">17072329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469. doi: 10.1038/s41586-020-2588-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId>
            <ArticleId IdType="pmc">PMC7477538</ArticleId>
            <ArticleId IdType="pubmed">32717743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caricchio R., Gallucci M., Dass C., Zhang X., Gallucci S., Fleece D. Preliminary predictive criteria for COVID-19 cytokine storm. Ann. Rheum. Dis. 2021;80:88–95. doi: 10.1136/annrheumdis-2020-218323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-218323</ArticleId>
            <ArticleId IdType="pubmed">32978237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masso-Silva J.A., Moshensky A., Lam M.T.Y., Odish M.F., Patel A., Xu L. Increased Peripheral Blood Neutrophil Activation Phenotypes and Neutrophil Extracellular Trap Formation in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients: A Case Series and Review of the Literature. Clin. Infect. Dis. 2022;74:479–489. doi: 10.1093/cid/ciab437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciab437</ArticleId>
            <ArticleId IdType="pmc">PMC8241438</ArticleId>
            <ArticleId IdType="pubmed">33988226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo W., Li Y.X., Jiang L.J., Chen Q., Wang T., Ye D.W. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol. Sci. 2020;41:531–543. doi: 10.1016/j.tips.2020.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2020.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC7298494</ArticleId>
            <ArticleId IdType="pubmed">32580895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrar Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front. Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId>
            <ArticleId IdType="pmc">PMC7308649</ArticleId>
            <ArticleId IdType="pubmed">32612617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012;76:16–32. doi: 10.1128/MMBR.05015-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId>
            <ArticleId IdType="pmc">PMC3294426</ArticleId>
            <ArticleId IdType="pubmed">22390970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Liu X., Wu S., Chen S., Li Y., Nong L. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients with Pneumonia: Analysis of Disease Characteristics. J. Infect. Dis. 2020;222:1444–1451. doi: 10.1093/infdis/jiaa387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiaa387</ArticleId>
            <ArticleId IdType="pmc">PMC7337810</ArticleId>
            <ArticleId IdType="pubmed">32601708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI137244</ArticleId>
            <ArticleId IdType="pmc">PMC7190990</ArticleId>
            <ArticleId IdType="pubmed">32217835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ather J.L., Ckless K., Martin R., Foley K.L., Suratt B.T., Boyson J.E. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J. Immunol. 2011;187:64–73. doi: 10.4049/jimmunol.1100500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1100500</ArticleId>
            <ArticleId IdType="pmc">PMC3119761</ArticleId>
            <ArticleId IdType="pubmed">21622869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mridha A.R., Wree A., Robertson A.A.B., Yeh M.M., Johnson C.D., Van Rooyen D.M. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 2017;66:1037–1046. doi: 10.1016/j.jhep.2017.01.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.01.022</ArticleId>
            <ArticleId IdType="pmc">PMC6536116</ArticleId>
            <ArticleId IdType="pubmed">28167322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L., Ding Y., Zhang Q., Che X., He Y., Shen H. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 2006;210:288–297. doi: 10.1002/path.2067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2067</ArticleId>
            <ArticleId IdType="pmc">PMC7167655</ArticleId>
            <ArticleId IdType="pubmed">17031779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alosaimi B., Hamed M.E., Naeem A., Alsharef A.A., AlQahtani S.Y., AlDosari K.M. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine. 2020;126:154895. doi: 10.1016/j.cyto.2019.154895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2019.154895</ArticleId>
            <ArticleId IdType="pmc">PMC7128721</ArticleId>
            <ArticleId IdType="pubmed">31706200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau S.K.P., Lau C.C.Y., Chan K.H., Li C.P.Y., Chen H., Jin D.Y. Delayed induction of pro-inflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. Pt 12J. Gen. Virol. 2013;94:2679–2690. doi: 10.1099/vir.0.055533-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/vir.0.055533-0</ArticleId>
            <ArticleId IdType="pubmed">24077366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2020.108393</ArticleId>
            <ArticleId IdType="pmc">PMC7102614</ArticleId>
            <ArticleId IdType="pubmed">32222466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dostert C., Pétrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–677. doi: 10.1126/science.1156995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1156995</ArticleId>
            <ArticleId IdType="pmc">PMC2396588</ArticleId>
            <ArticleId IdType="pubmed">18403674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassel S.L., Eisenbarth S.C., Iyer S.S., Sadler J.J., Colegio O.R., Tephly L.A. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. USA. 2008;105:9035–9040. doi: 10.1073/pnas.0803933105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0803933105</ArticleId>
            <ArticleId IdType="pmc">PMC2449360</ArticleId>
            <ArticleId IdType="pubmed">18577586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruz C.M., Rinna A., Forman H.J., Ventura A.L., Persechini P.M. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of pro-inflammatory cytokines in macrophages. J. Biol. Chem. 2007;282:2871–2879. doi: 10.1074/jbc.M608083200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M608083200</ArticleId>
            <ArticleId IdType="pmc">PMC2693903</ArticleId>
            <ArticleId IdType="pubmed">17132626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becher B., Tugues S., Greter M. GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity. 2016;45:963–973. doi: 10.1016/j.immuni.2016.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.10.026</ArticleId>
            <ArticleId IdType="pubmed">27851925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guilliams M., De Kleer I., Henri S., Post S., Vanhoutte L., De Prijck S. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 2013;210:1977–1992. doi: 10.1084/jem.20131199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20131199</ArticleId>
            <ArticleId IdType="pmc">PMC3782041</ArticleId>
            <ArticleId IdType="pubmed">24043763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton J.A. GM-CSF in inflammation. J. Exp. Med. 2020;217:e20190945. doi: 10.1084/jem.20190945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20190945</ArticleId>
            <ArticleId IdType="pmc">PMC7037240</ArticleId>
            <ArticleId IdType="pubmed">31611249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S., Gautam V., Naseem S. Acute-phase proteins: As diagnostic tool. J. Pharm. Bioallied Sci. 2011;3:118–127. doi: 10.4103/0975-7406.76489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0975-7406.76489</ArticleId>
            <ArticleId IdType="pmc">PMC3053509</ArticleId>
            <ArticleId IdType="pubmed">21430962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yusof Y.A.M., Haque M. Biomarkers for The Detection of SARS-CoV2-Virus and in the Prediction of COVID-19 Infection Severity. J. App. Pharm. Sci. 2022;12:i–v. doi: 10.7324/JAPS.2022.1202ed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7324/JAPS.2022.1202ed</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M., Chen X., Xu Y. A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 Wuhan, China. Med. Sci. Monit. 2020;26:e926393. doi: 10.12659/MSM.926393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.926393</ArticleId>
            <ArticleId IdType="pmc">PMC7507794</ArticleId>
            <ArticleId IdType="pubmed">32914767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali A., Noman M., Guo Y., Liu X., Zhang R., Zhou J. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Sci. Rep. 2021;11:5975. doi: 10.1038/s41598-021-85426-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-85426-9</ArticleId>
            <ArticleId IdType="pmc">PMC7971049</ArticleId>
            <ArticleId IdType="pubmed">33727641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noris M., Benigni A., Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314–322. doi: 10.1016/j.kint.2020.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2020.05.013</ArticleId>
            <ArticleId IdType="pmc">PMC7246017</ArticleId>
            <ArticleId IdType="pubmed">32461141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan Y.Y., Yin C.H., Yao Y.M. Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. Front. Immunol. 2021;12:720363. doi: 10.3389/fimmu.2021.720363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.720363</ArticleId>
            <ArticleId IdType="pmc">PMC8382792</ArticleId>
            <ArticleId IdType="pubmed">34447386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stringer D., Braude P., Myint P.K., Evans L., Collins J.T., Verduri A. The role of C-reactive protein as a prognostic marker in COVID-19. Int. J. Epidemiol. 2021;50:420–429. doi: 10.1093/ije/dyab012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ije/dyab012</ArticleId>
            <ArticleId IdType="pmc">PMC7989395</ArticleId>
            <ArticleId IdType="pubmed">33683344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J., Covassin N., Fan Z., Singh P., Gao W., Li G. Association Between Hypoxemia and Mortality in Patients with COVID-19. Mayo Clin. Proc. 2020;95:1138–1147. doi: 10.1016/j.mayocp.2020.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2020.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC7151468</ArticleId>
            <ArticleId IdType="pubmed">32376101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L. C-reactive protein levels in the early stage of COVID-19. Med. Mal. Infect. 2020;50:332–334. doi: 10.1016/j.medmal.2020.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medmal.2020.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC7146693</ArticleId>
            <ArticleId IdType="pubmed">32243911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Favresse J., Lippi G., Roy P.M., Chatelain B., Jacqmin H., Ten Cate H. D-dimer: Preanalytical, analytical, post-analytical variables, and clinical applications. Crit. Rev. Clin. Lab. Sci. 2018;55:548–577. doi: 10.1080/10408363.2018.1529734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10408363.2018.1529734</ArticleId>
            <ArticleId IdType="pubmed">30694079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley R.S., Gilbert A.R., Dalton J.B., Pai S., McPherson R.A. Widely Used Types and Clinical Applications of D-Dimer Assay. Lab. Med. 2016;47:90–102. doi: 10.1093/labmed/lmw001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/labmed/lmw001</ArticleId>
            <ArticleId IdType="pubmed">27016528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poudel A., Poudel Y., Adhikari A., Aryal B.B., Dangol D., Bajracharya T. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS ONE. 2021;16:e0256744.  doi: 10.1371/journal.pone.0256744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0256744</ArticleId>
            <ArticleId IdType="pmc">PMC8389366</ArticleId>
            <ArticleId IdType="pubmed">34437642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y., Cao J., Wang Q., Shi Q., Liu K., Luo Z. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case-control study. J. Intensive Care. 2020;8:49. doi: 10.1186/s40560-020-00466-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40560-020-00466-z</ArticleId>
            <ArticleId IdType="pmc">PMC7348129</ArticleId>
            <ArticleId IdType="pubmed">32665858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:1421–1424. doi: 10.1111/jth.14830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.14830</ArticleId>
            <ArticleId IdType="pmc">PMC7262324</ArticleId>
            <ArticleId IdType="pubmed">32271988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Brüggen M.C. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–1581. doi: 10.1111/all.14364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.14364</ArticleId>
            <ArticleId IdType="pmc">PMC7272948</ArticleId>
            <ArticleId IdType="pubmed">32396996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debuc B., Smadja D.M. Is COVID-19 a New Hematologic Disease? Stem Cell Rev. Rep. 2021;17:4–8. doi: 10.1007/s12015-020-09987-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-020-09987-4</ArticleId>
            <ArticleId IdType="pmc">PMC7217340</ArticleId>
            <ArticleId IdType="pubmed">32399806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020;10:102–108. doi: 10.1016/j.jpha.2020.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpha.2020.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC7104082</ArticleId>
            <ArticleId IdType="pubmed">32282863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson M.P., Jack A.S. Coronavirus disease 2019 (COVID-19) in neurology and neurosurgery: A scoping review of the early literature. Clin. Neurol. Neurosurg. 2020;193:105866. doi: 10.1016/j.clineuro.2020.105866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2020.105866</ArticleId>
            <ArticleId IdType="pmc">PMC7179494</ArticleId>
            <ArticleId IdType="pubmed">32389893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: Pathogenesis, cytokine storm, and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. doi: 10.1016/j.cytogfr.2020.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2020.05.002</ArticleId>
            <ArticleId IdType="pmc">PMC7204669</ArticleId>
            <ArticleId IdType="pubmed">32418715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId>
            <ArticleId IdType="pmc">PMC7727315</ArticleId>
            <ArticleId IdType="pubmed">33264547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanmohammadi S., Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J. Med. Virol. 2021;93:2735–2739. doi: 10.1002/jmv.26826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26826</ArticleId>
            <ArticleId IdType="pmc">PMC8014260</ArticleId>
            <ArticleId IdType="pubmed">33506952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trasino S.E. A role for retinoids in the treatment of COVID-19? Clin. Exp. Pharmacol. Physiol. 2020;47:1765–1767. doi: 10.1111/1440-1681.13354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1440-1681.13354</ArticleId>
            <ArticleId IdType="pubmed">32459003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onomoto K., Onoguchi K., Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: Interaction between host and viral factors. Cell. Mol. Immunol. 2021;18:539–555. doi: 10.1038/s41423-020-00602-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-020-00602-7</ArticleId>
            <ArticleId IdType="pmc">PMC7812568</ArticleId>
            <ArticleId IdType="pubmed">33462384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T., Feng M., Wen Z., He Y., Lin W., Zhang M. Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections. J. Inflamm. Res. 2021;14:5475–5487. doi: 10.2147/JIR.S329697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JIR.S329697</ArticleId>
            <ArticleId IdType="pmc">PMC8550203</ArticleId>
            <ArticleId IdType="pubmed">34720596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Samkari H., Berliner N. Hemophagocytic Lymphohistiocytosis. Annu. Rev. Pathol. 2018;13:27–49. doi: 10.1146/annurev-pathol-020117-043625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pathol-020117-043625</ArticleId>
            <ArticleId IdType="pubmed">28934563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006;355:1018–1028. doi: 10.1056/NEJMoa063842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa063842</ArticleId>
            <ArticleId IdType="pubmed">16908486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts K.A., Colley L., Agbaedeng T.A., Ellison-Hughes G.M., Ross M.D. Vascular Manifestations of COVID-19—Thromboembolism and Microvascular Dysfunction. Front. Cardiovasc. Med. 2020;7:598400. doi: 10.3389/fcvm.2020.598400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcvm.2020.598400</ArticleId>
            <ArticleId IdType="pmc">PMC7649150</ArticleId>
            <ArticleId IdType="pubmed">33195487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joly B.S., Siguret V., Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46:1603–1606. doi: 10.1007/s00134-020-06088-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-020-06088-1</ArticleId>
            <ArticleId IdType="pmc">PMC7225398</ArticleId>
            <ArticleId IdType="pubmed">32415314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Elia R.V., Harrison K., Oyston P.C., Lukaszewski R.A., Clark G.C. Targeting the “cytokine storm” for therapeutic benefit. Clin. Vaccine Immunol. 2013;20:319–327. doi: 10.1128/CVI.00636-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00636-12</ArticleId>
            <ArticleId IdType="pmc">PMC3592351</ArticleId>
            <ArticleId IdType="pubmed">23283640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J.Y., Alvarez C.A., Cobb B.A. Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy. Elife. 2021;10:e57417. doi: 10.7554/eLife.57417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.57417</ArticleId>
            <ArticleId IdType="pmc">PMC7899647</ArticleId>
            <ArticleId IdType="pubmed">33617447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L.Y.C., Hoiland R.L., Stukas S., Wellington C.L., Sekhon M.S. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur. Respir. J. 2020;56:2003006. doi: 10.1183/13993003.03006-2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.03006-2020</ArticleId>
            <ArticleId IdType="pmc">PMC7474149</ArticleId>
            <ArticleId IdType="pubmed">32883678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalli G., Dinarello C.A. Suppression of inflammation and acquired immunity by IL-37. Immunol. Rev. 2018;281:179–190. doi: 10.1111/imr.12605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12605</ArticleId>
            <ArticleId IdType="pubmed">29247987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q., Wang R.S., Qu G.Q., Wang Y.Y., Liu P., Zhu Y.Z. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36:21–23. doi: 10.12116/j.issn.1004-5619.2020.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12116/j.issn.1004-5619.2020.01.005</ArticleId>
            <ArticleId IdType="pubmed">32198987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su H., Yang M., Wan C., Yi L.X., Tang F., Zhu H.Y., Nie X., Zhang C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219–227. doi: 10.1016/j.kint.2020.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2020.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC7194105</ArticleId>
            <ArticleId IdType="pubmed">32327202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wichmann D., Sperhake J.P., Lütgehetmann M., Steurer S., Edler C., Heinemann A. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann. Intern. Med. 2020;173:268–277. doi: 10.7326/M20-2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M20-2003</ArticleId>
            <ArticleId IdType="pmc">PMC7240772</ArticleId>
            <ArticleId IdType="pubmed">32374815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId>
            <ArticleId IdType="pmc">PMC7164771</ArticleId>
            <ArticleId IdType="pubmed">32085846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da B.L., Mitchell R.A., Lee B.T., Perumalswami P., Im G.Y., Agarwal R., Schiano T.D. Kinetic patterns of liver enzyme elevation with COVID-19 in the USA. Eur. J. Gastroenterol. Hepatol. 2020;32:1466–1469. doi: 10.1097/MEG.0000000000001792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MEG.0000000000001792</ArticleId>
            <ArticleId IdType="pmc">PMC7299115</ArticleId>
            <ArticleId IdType="pubmed">32501877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kermali M., Khalsa R.K., Pillai K., Ismail Z., Harky A. The role of biomarkers in diagnosis of COVID-19—A systematic review. Life Sci. 2020;254:117788. doi: 10.1016/j.lfs.2020.117788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.117788</ArticleId>
            <ArticleId IdType="pmc">PMC7219356</ArticleId>
            <ArticleId IdType="pubmed">32475810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobiczyk E., Winiarska H.M., Springer D., Wysocka E., Cofta S. Clinical significance of basic laboratory parameters in predicting the use of various methods of oxygen supplementation in COVID-19. Adv. Respir. Med. 2022;90:77–85. doi: 10.5603/ARM.a2022.0016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/ARM.a2022.0016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D., Du Q., Yan S., Guo X.G., He Y., Zhu G., Zhao K., Ouyang S. Liver injury in COVID-19: Clinical features and treatment management. Virol. J. 2021;18:121. doi: 10.1186/s12985-021-01593-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12985-021-01593-1</ArticleId>
            <ArticleId IdType="pmc">PMC8188532</ArticleId>
            <ArticleId IdType="pubmed">34108015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann A., Prosch H., Zehetmayer S., Gysan M.R., Bernitzky D., Vonbank K., Idzko M., Gompelmann D. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS ONE. 2021;16:e0258351.  doi: 10.1371/journal.pone.0258351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0258351</ArticleId>
            <ArticleId IdType="pmc">PMC8553152</ArticleId>
            <ArticleId IdType="pubmed">34710097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thachil J., Cushman M., Srivastava A. A proposal for staging COVID-19 coagulopathy. Res. Pract. Thromb. Haemost. 2020;4:731–736. doi: 10.1002/rth2.12372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rth2.12372</ArticleId>
            <ArticleId IdType="pmc">PMC7272892</ArticleId>
            <ArticleId IdType="pubmed">32685880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartziokas K., Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Med. Clin. 2021;156:37. doi: 10.1016/j.medcli.2020.07.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medcli.2020.07.043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry B.M., Aggarwal G., Wong J., Benoit S., Vikse J., Plebani M., Lippi G. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am. J. Emerg. Med. 2020;38:1722–1726. doi: 10.1016/j.ajem.2020.05.073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajem.2020.05.073</ArticleId>
            <ArticleId IdType="pmc">PMC7251362</ArticleId>
            <ArticleId IdType="pubmed">32738466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szarpak L., Ruetzler K., Safiejko K., Hampel M., Pruc M., Kanczuga-Koda L., Filipiak K.J., Jaguszewski M.J. Lactate dehydrogenase level as a COVID-19 severity marker. Am. J. Emerg. Med. 2021;45:638–639. doi: 10.1016/j.ajem.2020.11.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajem.2020.11.025</ArticleId>
            <ArticleId IdType="pmc">PMC7666711</ArticleId>
            <ArticleId IdType="pubmed">33246860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbasi J. Researchers Investigate What COVID-19 Does to the Heart. JAMA. 2021;325:808–811. doi: 10.1001/jama.2021.0107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.0107</ArticleId>
            <ArticleId IdType="pubmed">33566089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majure D.T., Gruberg L., Saba S.G., Kvasnovsky C., Hirsch J.S., Jauhar R. Northwell Health COVID-19 Research Consortium. Usefulness of Elevated Troponin to Predict Death in Patients with COVID-19 and Myocardial Injury. Am. J. Cardiol. 2021;138:100–106. doi: 10.1016/j.amjcard.2020.09.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2020.09.060</ArticleId>
            <ArticleId IdType="pmc">PMC7550867</ArticleId>
            <ArticleId IdType="pubmed">33058800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tersalvi G., Vicenzi M., Calabretta D., Biasco L., Pedrazzini G., Winterton D. Elevated Troponin in Patients with Coronavirus Disease 2019: Possible Mechanisms. J. Card. Fail. 2020;26:470–475. doi: 10.1016/j.cardfail.2020.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cardfail.2020.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC7166030</ArticleId>
            <ArticleId IdType="pubmed">32315733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo A.K.G., Milby K.M., Caparroz A.L.M.A., Pinto A.C.P.N., Santos R.R.P., Rocha A.P., Ferreira G.A., Souza V.A., Valadares L.D.A., Vieira R.M.R.A. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PLoS ONE. 2021;16:e0253894.  doi: 10.1371/journal.pone.0253894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0253894</ArticleId>
            <ArticleId IdType="pmc">PMC8241122</ArticleId>
            <ArticleId IdType="pubmed">34185801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shcherbak S.G., Anisenkova A.Y., Mosenko S.V., Glotov O.S., Chernov A.N., Apalko S.V. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients. Front. Immunol. 2021;12:745515. doi: 10.3389/fimmu.2021.745515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.745515</ArticleId>
            <ArticleId IdType="pmc">PMC8631447</ArticleId>
            <ArticleId IdType="pubmed">34858403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Yin L., Patel J., Tang L., Huang Y. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis. J. Med. Virol. 2021;93:4358–4369. doi: 10.1002/jmv.26951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26951</ArticleId>
            <ArticleId IdType="pmc">PMC8250955</ArticleId>
            <ArticleId IdType="pubmed">33739452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avila-Nava A., Cortes-Telles A., Torres-Erazo D., López-Romero S., Chim Aké R., Gutiérrez Solis A.L. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. Cytokine. 2021;143:155543. doi: 10.1016/j.cyto.2021.155543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2021.155543</ArticleId>
            <ArticleId IdType="pmc">PMC8052471</ArticleId>
            <ArticleId IdType="pubmed">33896708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan F., Yang L., Li Y., Liang B., Li L., Ye T. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): A case-control study. Int. J. Med. Sci. 2020;17:1281–1292. doi: 10.7150/ijms.46614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijms.46614</ArticleId>
            <ArticleId IdType="pmc">PMC7294915</ArticleId>
            <ArticleId IdType="pubmed">32547323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Hao Y., Ou W., Ming F., Liang G., Qian Y. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: A cohort study. J. Transl. Med. 2020;18:406. doi: 10.1186/s12967-020-02571-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-020-02571-x</ArticleId>
            <ArticleId IdType="pmc">PMC7594951</ArticleId>
            <ArticleId IdType="pubmed">33121497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A., Marzook H., Ahmad F. Comorbidities and clinical complications associated with SARS-CoV-2 infection: An overview. Clin. Exp. Med. 2022:1–19. doi: 10.1007/s10238-022-00821-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10238-022-00821-4</ArticleId>
            <ArticleId IdType="pubmed">33990849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A.E. COVID-19, and comorbidities: Deleterious impact on infected patients. J. Infect. Public Health. 2020;13:1833–1839. doi: 10.1016/j.jiph.2020.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2020.07.014</ArticleId>
            <ArticleId IdType="pmc">PMC7402107</ArticleId>
            <ArticleId IdType="pubmed">32788073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siddiqi Z., Fatima J., Bhatt D., Shukla V., Malik M., Ashfaq A. Prevalence of Comorbidities in Survivors and Non-Survivors of Severe COVID-19 at a Dedicated COVID Care Centre. J. Assoc. Physicians India. 2022;70:11–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35062800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasmi A., Peana M., Pivina L., Srinath S., Gasmi Benahmed A., Semenova Y. Interrelations between COVID-19 and other disorders. Clin. Immunol. 2021;224:108651. doi: 10.1016/j.clim.2020.108651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2020.108651</ArticleId>
            <ArticleId IdType="pmc">PMC7833539</ArticleId>
            <ArticleId IdType="pubmed">33333255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramatillah D.L., Gan S.H., Pratiwy I., Syed Sulaiman S.A., Jaber A.A.S., Jusnita N. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. PLoS ONE. 2022;17:e0262438.  doi: 10.1371/journal.pone.0262438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0262438</ArticleId>
            <ArticleId IdType="pmc">PMC8789122</ArticleId>
            <ArticleId IdType="pubmed">35077495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buford T.W. Hypertension and aging. Ageing Res. Rev. 2016;26:96–111. doi: 10.1016/j.arr.2016.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2016.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC4768730</ArticleId>
            <ArticleId IdType="pubmed">26835847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kay A.M., Simpson C.L., Stewart J.A., Jr. The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification. J. Diabetes Res. 2016;2016:6809703. doi: 10.1155/2016/6809703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/6809703</ArticleId>
            <ArticleId IdType="pmc">PMC4980539</ArticleId>
            <ArticleId IdType="pubmed">27547766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazdanpanah F., Hamblin M.R., Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020;256:117900. doi: 10.1016/j.lfs.2020.117900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.117900</ArticleId>
            <ArticleId IdType="pmc">PMC7266583</ArticleId>
            <ArticleId IdType="pubmed">32502542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunnumakkara A.B., Rana V., Parama D., Banik K., Girisa S., Henamayee S., Thakur K.K., Dutta U., Garodia P., Gupta S.C. COVID-19, cytokines, inflammation, and spices: How are they related? Life Sci. 2021;284:119201. doi: 10.1016/j.lfs.2021.119201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2021.119201</ArticleId>
            <ArticleId IdType="pmc">PMC7884924</ArticleId>
            <ArticleId IdType="pubmed">33607159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId>
            <ArticleId IdType="pmc">PMC7146714</ArticleId>
            <ArticleId IdType="pubmed">32291094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18:1094–1099. doi: 10.1111/jth.14817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.14817</ArticleId>
            <ArticleId IdType="pubmed">32220112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llitjos J.F., Leclerc M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. 2020;18:1743–1746. doi: 10.1111/jth.14869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.14869</ArticleId>
            <ArticleId IdType="pmc">PMC7264774</ArticleId>
            <ArticleId IdType="pubmed">32320517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb. Res. 2020;194:101–115. doi: 10.1016/j.thromres.2020.06.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2020.06.029</ArticleId>
            <ArticleId IdType="pmc">PMC7305763</ArticleId>
            <ArticleId IdType="pubmed">32788101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill J.T., Erkan D., Winakur J., James J.A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat. Rev. Rheumatol. 2020;16:581–589. doi: 10.1038/s41584-020-0474-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-0474-5</ArticleId>
            <ArticleId IdType="pmc">PMC7391481</ArticleId>
            <ArticleId IdType="pubmed">32733003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.14768</ArticleId>
            <ArticleId IdType="pmc">PMC7166509</ArticleId>
            <ArticleId IdType="pubmed">32073213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Liu Z., Wu G., Yi M., Chen Y., Li K., Xu X., Xiao L., Wu Q., Chen J. D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized with COVID-19 in Leishenshan Hospital, Wuhan, China. Front. Pharmacol. 2020;11:600592. doi: 10.3389/fphar.2020.600592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.600592</ArticleId>
            <ArticleId IdType="pmc">PMC7779604</ArticleId>
            <ArticleId IdType="pubmed">33408630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aires R.B., Soares A.A.S.M., Gomides A.P.M., Nicola A.M., Teixeira-Carvalho A., da Silva D.L.M. Thromboelastometry demonstrates endogenous coagulation activation in nonsevere and severe COVID-19 patients and has applicability as a decision algorithm for intervention. PLoS One. 2022;17:e0262600. doi: 10.1371/journal.pone.0262600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0262600</ArticleId>
            <ArticleId IdType="pmc">PMC8759688</ArticleId>
            <ArticleId IdType="pubmed">35030224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: Immunity, inflammation, and intervention. Nat. Rev. Immunol. 2020;20:363–374. doi: 10.1038/s41577-020-0311-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId>
            <ArticleId IdType="pmc">PMC7187672</ArticleId>
            <ArticleId IdType="pubmed">32346093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen S.F., Ho Y.C. SARS-CoV-2: A storm is raging. J. Clin. Investig. 2020;130:2202–2205. doi: 10.1172/JCI137647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI137647</ArticleId>
            <ArticleId IdType="pmc">PMC7190904</ArticleId>
            <ArticleId IdType="pubmed">32217834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magadum A., Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells. 2020;9:2508.  doi: 10.3390/cells9112508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9112508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavazzi G., Pellegrini C., Maurelli M., Belliato M., Sciutti F., Bottazzi A., Sepe P.A., Resasco T., Camporotondo R., Bruno R. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 2020;22:911–915. doi: 10.1002/ejhf.1828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.1828</ArticleId>
            <ArticleId IdType="pmc">PMC7262276</ArticleId>
            <ArticleId IdType="pubmed">32275347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId>
            <ArticleId IdType="pmc">PMC7190011</ArticleId>
            <ArticleId IdType="pubmed">32217556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W.L., Toh H.S., Liao C.T., Chang W.T. Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. Acta Cardiol. Sin. 2021;37:9–17. doi: 10.6515/ACS.202101_37(1).20200913A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6515/ACS.202101_37(1).20200913A</ArticleId>
            <ArticleId IdType="pmc">PMC7814323</ArticleId>
            <ArticleId IdType="pubmed">33488023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmadian E., Hosseiniyan Khatibi S.M., Razi Soofiyani S., Abediazar S., Shoja M.M., Ardalan M., Zununi Vahed S. COVID-19, and kidney injury: Pathophysiology and molecular mechanisms. Rev. Med. Virol. 2021;31:e2176. doi: 10.1002/rmv.2176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rmv.2176</ArticleId>
            <ArticleId IdType="pmc">PMC7646060</ArticleId>
            <ArticleId IdType="pubmed">33022818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buonaguro F.M., Ascierto P.A., Morse G.D., Buonaguro L., Puzanov I., Tornesello M.L., Bréchot C., Gallo R.C. COVID-19: Time for a paradigm change. Rev. Med. Virol. 2020;30:e2134. doi: 10.1002/rmv.2134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rmv.2134</ArticleId>
            <ArticleId IdType="pmc">PMC7361272</ArticleId>
            <ArticleId IdType="pubmed">32618072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X.Q., Liu H., Meng Y., Yin H.Y., Gao W.Y., Yang X., Xu D.S., Cai X.D., Guan Y., Lerman L.O. Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study. J. Med. Virol. 2021;93:6641–6652. doi: 10.1002/jmv.27234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27234</ArticleId>
            <ArticleId IdType="pmc">PMC8426723</ArticleId>
            <ArticleId IdType="pubmed">34314040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabb H. Kidney diseases in the time of COVID-19: Major challenges to patient care. J. Clin. Investig. 2020;130:2749–2751. doi: 10.1172/JCI138871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI138871</ArticleId>
            <ArticleId IdType="pmc">PMC7259985</ArticleId>
            <ArticleId IdType="pubmed">32250968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020;296:E119–E120. doi: 10.1148/radiol.2020201187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2020201187</ArticleId>
            <ArticleId IdType="pmc">PMC7233386</ArticleId>
            <ArticleId IdType="pubmed">32228363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shehata G.A., Lord K.C., Grudzinski M.C., Elsayed M., Abdelnaby R., Elshabrawy H.A. Neurological Complications of COVID-19: Underlying Mechanisms and Management. Int. J. Mol. Sci. 2021;22:4081.  doi: 10.3390/ijms22084081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22084081</ArticleId>
            <ArticleId IdType="pmc">PMC8071289</ArticleId>
            <ArticleId IdType="pubmed">33920904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertolini A., van de Peppel I.P., Bodewes F.A.J.A., Moshage H., Fantin A., Farinati F. Abnormal Liver Function Tests in Patients with COVID-19: Relevance and Potential Pathogenesis. Hepatology. 2020;72:1864–1872. doi: 10.1002/hep.31480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31480</ArticleId>
            <ArticleId IdType="pmc">PMC7404414</ArticleId>
            <ArticleId IdType="pubmed">32702162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J. Clin. Transl. Hepatol. 2020;8:18–24. doi: 10.14218/JCTH.2020.00018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14218/JCTH.2020.00018</ArticleId>
            <ArticleId IdType="pmc">PMC7132016</ArticleId>
            <ArticleId IdType="pubmed">32274342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar M.P., Mishra S., Jha D.K., Shukla J., Choudhury A., Mohindra R. Coronavirus disease (COVID-19) and the liver: A comprehensive systematic review and meta-analysis. Hepatol. Int. 2020;14:711–722. doi: 10.1007/s12072-020-10071-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12072-020-10071-9</ArticleId>
            <ArticleId IdType="pmc">PMC7335221</ArticleId>
            <ArticleId IdType="pubmed">32623633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:667–678. doi: 10.1016/S2468-1253(20)30126-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2468-1253(20)30126-6</ArticleId>
            <ArticleId IdType="pmc">PMC7217643</ArticleId>
            <ArticleId IdType="pubmed">32405603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anirvan P., Narain S., Hajizadeh N., Aloor F.Z., Singh S.P., Satapathy S.K. Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): Untangling the knots. Eur. J. Gastroenterol. Hepatol. 2021;33((Suppl. S1)):e42–e49. doi: 10.1097/MEG.0000000000002034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MEG.0000000000002034</ArticleId>
            <ArticleId IdType="pubmed">33405427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polak S.B., Van Gool I.C., Cohen D., von der Thüsen J.H., van Paassen J. A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol. 2020;33:2128–2138. doi: 10.1038/s41379-020-0603-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41379-020-0603-3</ArticleId>
            <ArticleId IdType="pmc">PMC7306927</ArticleId>
            <ArticleId IdType="pubmed">32572155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boeckmans J., Rodrigues R.M., Demuyser T., Piérard D., Vanhaecke T., Rogiers V. COVID-19, and drug-induced liver injury: A problem of plenty or a petty point? Arch. Toxicol. 2020;94:1367–1369. doi: 10.1007/s00204-020-02734-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00204-020-02734-1</ArticleId>
            <ArticleId IdType="pmc">PMC7138655</ArticleId>
            <ArticleId IdType="pubmed">32266419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Licata A., Minissale M.G., Distefano M., Montalto G. Liver injury, SARS-CoV-2 infection, and COVID-19: What physicians should really know? GastroHep. 2021;3:121–130. doi: 10.1002/ygh2.455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ygh2.455</ArticleId>
            <ArticleId IdType="pmc">PMC8207035</ArticleId>
            <ArticleId IdType="pubmed">34149320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitiello A., La Porta R., D’Aiuto V., Ferrara F. The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt. Liver J. 2021;11:11. doi: 10.1186/s43066-021-00082-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s43066-021-00082-y</ArticleId>
            <ArticleId IdType="pmc">PMC7838235</ArticleId>
            <ArticleId IdType="pubmed">34777865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu K., Patel J., Swiston C.  StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2022.  [(accessed on 9 March 2022)]. Ophthalmic Manifestations of Coronavirus (COVID-19) Available online:  https://www.ncbi.nlm.nih.gov/books/NBK556093/</Citation>
        </Reference>
        <Reference>
          <Citation>Nasiri N., Sharifi H., Bazrafshan A., Noori A., Karamouzian M., Sharifi A. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. J. Ophthalmic Vis. Res. 2021;16:103–112. doi: 10.18502/jovr.v16i1.8256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18502/jovr.v16i1.8256</ArticleId>
            <ArticleId IdType="pmc">PMC7841281</ArticleId>
            <ArticleId IdType="pubmed">33520133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Y., Wang K., Zhu Y., Lyu D., Yu Y., Li S. Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. Travel Med. Infect. Dis. 2021;44:102191. doi: 10.1016/j.tmaid.2021.102191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tmaid.2021.102191</ArticleId>
            <ArticleId IdType="pmc">PMC8574127</ArticleId>
            <ArticleId IdType="pubmed">34763068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bostanci Ceran B., Ozates S. Ocular manifestations of coronavirus disease 2019. Graefes Arch. Clin. Exp. Ophthalmol. 2020;258:1959–1963. doi: 10.1007/s00417-020-04777-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00417-020-04777-7</ArticleId>
            <ArticleId IdType="pmc">PMC7274940</ArticleId>
            <ArticleId IdType="pubmed">32504100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y., Liu J., Zhang D., Xu Z., Ji J., Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front. Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId>
            <ArticleId IdType="pmc">PMC7365923</ArticleId>
            <ArticleId IdType="pubmed">32754163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaye A.G., Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: A systematic review. PeerJ. 2020;8:e10322. doi: 10.7717/peerj.10322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7717/peerj.10322</ArticleId>
            <ArticleId IdType="pmc">PMC7643559</ArticleId>
            <ArticleId IdType="pubmed">33194450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boregowda U., Perisetti A., Nanjappa A., Gajendran M., Kutti Sridharan G., Goyal H. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. Front. Med. 2020;7:586221. doi: 10.3389/fmed.2020.586221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2020.586221</ArticleId>
            <ArticleId IdType="pmc">PMC7566918</ArticleId>
            <ArticleId IdType="pubmed">33123544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio-Rivas M., Forero C.G., Mora-Luján J.M., Montero A., Formiga F., Homs N.A. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. Pharmacotherapy. 2021;41:884–906. doi: 10.1002/phar.2627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.2627</ArticleId>
            <ArticleId IdType="pmc">PMC8661749</ArticleId>
            <ArticleId IdType="pubmed">34558742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio-Rivas M., Ronda M., Padulles A., Mitjavila F., Riera-Mestre A., García-Forero C. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. Int. J. Infect. Dis. 2020;101:290–297. doi: 10.1016/j.ijid.2020.09.1486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2020.09.1486</ArticleId>
            <ArticleId IdType="pmc">PMC7537652</ArticleId>
            <ArticleId IdType="pubmed">33035673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto S., Yoshizaki K., Uno K., Kitajima H., Arai T., Tamura Y. Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated with the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients with COVID-19. Front. Med. 2021;8:734838. doi: 10.3389/fmed.2021.734838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2021.734838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolilekas L., Loverdos K., Giannakaki S., Vlassi L., Levounets A., Zervas E. Can steroids reverse the severe COVID-19 induced “cytokine storm”? J. Med. Virol. 2020;92:2866–2869. doi: 10.1002/jmv.26165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26165</ArticleId>
            <ArticleId IdType="pmc">PMC7307112</ArticleId>
            <ArticleId IdType="pubmed">32530507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olbei M., Hautefort I., Modos D., Treveil A., Poletti M., Gul L. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients. Front. Immunol. 2021;12:629193. doi: 10.3389/fimmu.2021.629193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.629193</ArticleId>
            <ArticleId IdType="pmc">PMC7956943</ArticleId>
            <ArticleId IdType="pubmed">33732251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chifu I., Detomas M., Dischinger U., Kimpel O., Megerle F., Hahner S. Management of Patients with Glucocorticoid-Related Diseases and COVID-19. Front. Endocrinol. 2021;12:705214. doi: 10.3389/fendo.2021.705214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2021.705214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X., Feng Y.M., Ni J.X., Zhang J.Y., Liu L.M., Hu K. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021;100:116–126. doi: 10.1159/000512063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000512063</ArticleId>
            <ArticleId IdType="pmc">PMC7900459</ArticleId>
            <ArticleId IdType="pubmed">33486496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ranjbar K., Moghadami M., Mirahmadizadeh A., Fallahi M.J., Khaloo V., Shahriarirad R. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect. Dis. 2021;21:337.  doi: 10.1186/s12879-021-06045-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-021-06045-3</ArticleId>
            <ArticleId IdType="pmc">PMC8035859</ArticleId>
            <ArticleId IdType="pubmed">33838657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isidori A.M., Arnaldi G., Boscaro M., Falorni A., Giordano C., Giordano R. COVID-19 infection and glucocorticoids: Update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J. Endocrinol. Investig. 2020;43:1141–1147. doi: 10.1007/s40618-020-01266-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01266-w</ArticleId>
            <ArticleId IdType="pmc">PMC7182741</ArticleId>
            <ArticleId IdType="pubmed">32335855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghbash P.S., Eslami N., Shamekh A., Entezari-Maleki T., Baghi H.B. SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021;270:119124. doi: 10.1016/j.lfs.2021.119124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2021.119124</ArticleId>
            <ArticleId IdType="pmc">PMC7838580</ArticleId>
            <ArticleId IdType="pubmed">33508291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nardelli P., Pieri M., Fominskiy E., Scandroglio A.M. Cytokine adsorption and ECMO in patients with COVID-19. Lancet Respir. Med. 2021;9:e71. doi: 10.1016/S2213-2600(21)00285-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(21)00285-X</ArticleId>
            <ArticleId IdType="pmc">PMC8260103</ArticleId>
            <ArticleId IdType="pubmed">34242581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rybalko A., Voronin A.V., Karpun N.A. Cytokine adsorption and ECMO in patients with COVID-19. Lancet Respir. Med. 2021;9:e69–e70. doi: 10.1016/S2213-2600(21)00276-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(21)00276-9</ArticleId>
            <ArticleId IdType="pmc">PMC8260102</ArticleId>
            <ArticleId IdType="pubmed">34242579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohler H., Kaveri S. How IvIg Can Mitigate COVID-19 Disease: A Symmetrical Immune Network Model. Monoclon. Antibodies Immunodiagn. Immunother. 2021;40:17–20. doi: 10.1089/mab.2020.0041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/mab.2020.0041</ArticleId>
            <ArticleId IdType="pubmed">33513050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Cao W., Li T. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Front. Immunol. 2020;11:1660. doi: 10.3389/fimmu.2020.01660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01660</ArticleId>
            <ArticleId IdType="pmc">PMC7372093</ArticleId>
            <ArticleId IdType="pubmed">32760407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int. J. Antimicrob. Agents. 2020;55:105982. doi: 10.1016/j.ijantimicag.2020.105982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105982</ArticleId>
            <ArticleId IdType="pmc">PMC7161506</ArticleId>
            <ArticleId IdType="pubmed">32305588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gatti E., Piotto M., Lelii M., Pensabene M., Madini B., Cerrato L. Therapeutic Strategies for COVID-19 Lung Disease in Children. Front. Pediatr. 2022;10:829521. doi: 10.3389/fped.2022.829521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2022.829521</ArticleId>
            <ArticleId IdType="pmc">PMC8936419</ArticleId>
            <ArticleId IdType="pubmed">35321012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Zhao W., Liu J., Chen Z., Lv Q., Zhang Z. Immunotherapy Summary for Cytokine Storm in COVID-19. Front. Pharmacol. 2021;12:731847. doi: 10.3389/fphar.2021.731847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.731847</ArticleId>
            <ArticleId IdType="pmc">PMC8484328</ArticleId>
            <ArticleId IdType="pubmed">34603047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conti P., Pregliasco F.E., Calvisi V., Caraffa Al Gallenga C.E., Kritas S.K. Monoclonal antibody therapy in COVID-19. J. Biol. Regul. Homeost. Agents. 2021;35:423–427. doi: 10.23812/Conti_Edit_35_2_1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.23812/Conti_Edit_35_2_1</ArticleId>
            <ArticleId IdType="pubmed">33904269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C., Wang C., Wang H., Yang C., Cai F., Zeng F. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. Clin. Transl. Sci. 2020;13:1087–1095. doi: 10.1111/cts.12880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cts.12880</ArticleId>
            <ArticleId IdType="pmc">PMC7719364</ArticleId>
            <ArticleId IdType="pubmed">32881340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gozzo L., Viale P., Longo L., Vitale D.C., Drago F. The Potential Role of Heparin in Patients with COVID-19: Beyond the Anticoagulant Effect. A Review. Front. Pharmacol. 2020;11:1307. doi: 10.3389/fphar.2020.01307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.01307</ArticleId>
            <ArticleId IdType="pmc">PMC7472559</ArticleId>
            <ArticleId IdType="pubmed">32973526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drago F., Gozzo L., Li L., Stella A., Cosmi B. Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. Front. Pharmacol. 2020;11:579886. doi: 10.3389/fphar.2020.579886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.579886</ArticleId>
            <ArticleId IdType="pmc">PMC7525088</ArticleId>
            <ArticleId IdType="pubmed">33041824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P., Matthay M.A., Calfee C.S. Is a “Cytokine Storm” Relevant to COVID-19? JAMA Intern. Med. 2020;180:1152–1154. doi: 10.1001/jamainternmed.2020.3313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2020.3313</ArticleId>
            <ArticleId IdType="pubmed">32602883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calfee C.S., Delucchi K., Parsons P.E., Thompson B.T., Ware L.B., Matthay M.A. Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomized controlled trials. Lancet Respir. Med. 2014;2:611–620. doi: 10.1016/S2213-2600(14)70097-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(14)70097-9</ArticleId>
            <ArticleId IdType="pmc">PMC4154544</ArticleId>
            <ArticleId IdType="pubmed">24853585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong C.K.H., Wan E.Y.F., Luo S., Ding Y., Lau E.H.Y., Ling P. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. EClinicalMedicine. 2021;32:100743. doi: 10.1016/j.eclinm.2021.100743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eclinm.2021.100743</ArticleId>
            <ArticleId IdType="pmc">PMC7881744</ArticleId>
            <ArticleId IdType="pubmed">33615206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010;11:1014–1022. doi: 10.1038/ni.1944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1944</ArticleId>
            <ArticleId IdType="pmc">PMC3537119</ArticleId>
            <ArticleId IdType="pubmed">20935647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banchereau J., Pascual V., O’Garra A. From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat. Immunol. 2012;13:925–931. doi: 10.1038/ni.2406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2406</ArticleId>
            <ArticleId IdType="pmc">PMC3609707</ArticleId>
            <ArticleId IdType="pubmed">22990890</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
